SAMHD1

SAM domain and HD domain 1

Structure of the catalytic core of human SAMHD1. PDB 3u1n.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols SAMHD1 ; CHBL2; DCIP; HDDC1; MOP-5; SBBI88
External IDs OMIM: 606754 MGI: 1927468 HomoloGene: 9160 GeneCards: SAMHD1 Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 25939 56045
Ensembl ENSG00000101347 ENSMUSG00000027639
UniProt Q9Y3Z3 Q60710
RefSeq (mRNA) NM_015474 NM_001139520
RefSeq (protein) NP_056289 NP_001132992
Location (UCSC) Chr 20:
36.89 – 36.95 Mb
Chr 2:
157.1 – 157.14 Mb
PubMed search

SAM domain and HD domain-containing protein 1 is a protein that in humans is encoded by the SAMHD1 gene. SAMHD1 is a cellular enzyme, responsible for blocking replication of HIV in dendritic cells,[1] macrophages[2] and monocytes.[3] It is an enzyme that exhibits phosphohydrolase activity,[4][5] converting nucleotide triphosphates (NTPs) to triphosphate and a nucleoside (i.e. nucleotides without a phosphate group). In doing so, SAMHD1 depletes the pool of NTPs available to a reverse transcriptase for viral cDNA synthesis and thus prevents viral replication.[6] SAMHD1 has also shown nuclease activity,[7] and a ribonuclease activity has been recently described to be required for HIV-1 restriction.[8]

Nomenclature

The SAMHD1 protein is also known as:

Gene

The gene encoding human SAMHD1 was originally identified in a human dendritic cell cDNA library as an orthologue of a mouse gene IFN-γ-induced gene Mg11.[10] The SAMHD1 gene is located on chromosome 20. SAMHD1 spans 59,532 bp of genomic sequence (chromosome 20:34,954,059–35,013,590) in 16 exons and encodes a 626 amino-acid (aa) protein with a molecular weight of 72.2 kDa.[11][12] SAMHD1 expressed in both cycling and noncycling cells, but the antiviral activity of SAMHD1 is limited to noncycling cells.[13]

Structure

The SAMHD1 is 626 amino acids (aa) long and has 2 domains:

a. Sterile Alpha Motif (SAM) domain: residues 45 – 110 aa.[14][15] In general, SAM domains are known to function as protein–protein and protein–nucleic acid interactions in organisms from yeast to humans, docking sites for kinases, signal transduction and regulation of transcription.[16][17]

b. Histidine- Aspartic (HD) domain-containing protein 1: residues 164 – 319 aa.[14][15] HD domains proteins are characterized by a doublet of histidine and aspartic acid catalyticresidues, and have been shown to possess putative nuclease, dGTP triphosphatase, phosphatase or phosphodiesterase activities.[16][18]

A crystal structure of a SAMHD1 fragment comprising catalytic core reveals that the protein is dimeric.[5] Also studies have shown that SAMHD1 oligomerizes and forms tetramers.[19] SAMHD1 is phosphorylated on residue T592 in cycling cells but that this phosphorylation is lost when cells are in a noncycling state. 13.[20]

Function

Mutations in SAMHD1 are found in Aicardi–Goutières syndrome (AGS), “a hereditary autoimmune encephalopathy that is characterized by aberrant production of type I interferon (IFN) and symptoms mimicking congenital viral infection”.[15] Monocytes isolated from individuals with AGS are highly susceptible to HIV-1.[3]

SAMHD1 was identified as a host protein that is bound and blocked by lentiviral protein, Vpx. Vpx promotes macrophage and DC infection by targeting SAMHD1.[21]

The human SAMHD1 protein has dNTP triphosphatase activity, specifically dGTP-stimulated dNTP triphosphohydrolase activity, and nuclease activity against single-stranded DNA and RNA which is associated with its HD domain.[7][22] Other studies demonstrated that silencing SAMHD1 enhanced HIV-1 and SIV Δvpx infection of myeloid cells, also enhances HIV-1 infection of resting CD4+ T cells.[13][22]

Role in disease

Aicardi-Goutieres syndrome

16 mutations in the SAMHD1 gene have been identified in patients with Aicardi-Goutieres syndrome. Mutations result in a SAMHD1 less functional protein. However, it is not known how this protein dysfunction leads to immune system abnormalities, inflammatory damage to the brain and skin, and other characteristics of this syndrome.[3][15]

Restriction viral infection

SAMHD1 was identified as the cellular protein responsible of the reverse transcription block to HIV-1 infection observed in myeloid cells as well as in quiescent CD4+ T cells.SAMHD1 inhibits HIV-1 infection in myeloid cells by limiting the intracellular pool of dNTPs.[21] The dNTP triphosphohydrolase activity of SAMHD1 has been proposed to reduce the intracellular dNTP level, restricting HIV-1 replication and preventing activation of the immune system, a nuclease activity against single-stranded (ss)DNAs and RNAs, as well as against RNA in DNA/RNA hybrids.[16][21] Retroviral restriction ability of SAMHD1 is regulated by phosphorylation, for this purpose SAMHD1 associates with the cyclin A2/CDK1 complex that mediates its phosphorylation at threonine 592. Phosphorylated SAMHD1 has been observed to have minimal to no activity in cycling cells. Conversely, unphosphorylated SamHD1 in non-cycling cells have potent restriction activity.[20]

References

  1. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Ségéral E, Yatim A, Emiliani S, Schwartz O, Benkirane M (June 2011). "SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx". Nature 474 (7353): 654–7. doi:10.1038/nature10117. PMC 3595993. PMID 21613998.
  2. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J (June 2011). "Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein". Nature 474 (7353): 658–61. doi:10.1038/nature10195. PMC 3179858. PMID 21720370.
  3. 1 2 3 Berger A, Sommer AF, Zwarg J, Hamdorf M, Welzel K, Esly N, Panitz S, Reuter A, Ramos I, Jatiani A, Mulder LC, Fernandez-Sesma A, Rutsch F, Simon V, König R, Flory E (December 2011). "SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection". PLOS Pathogens 7 (12): e1002425. doi:10.1371/journal.ppat.1002425. PMC 3234228. PMID 22174685.
  4. Powell RD, Holland PJ, Hollis T, Perrino FW. (December 2011). "Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase". J Biol Chem 286 (51): 43596–600. doi:10.1074/jbc.C111.317628. PMC 3243528. PMID 22069334.
  5. 1 2 Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, de Carvalho LP, Stoye JP, Crow YJ, Taylor IA, Webb M (December 2011). "HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase". Nature 480 (7377): 379–82. doi:10.1038/nature10623. PMID 22056990.
  6. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau NR, Kim B, Margottin-Goguet F (2012). "SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates". Nature Immunology 13: 223–228. doi:10.1038/ni.2236. PMC 3771401. PMID 22327569.
  7. 1 2 Beloglazova N, Flick R, Tchigvintsev A, Brown G, Popovic A, Nocek B, Yakunin AF. “Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction”. "J Biol Chem. 2013 Mar 22;288(12):8101-10". J Biol Chem 288 (12): 8101–10. Mar 2013. doi:10.1074/jbc.M112.431148. PMID 23364794.
  8. Ryoo, J; Choi, J; Oh, C; Kim, S; Seo, M; Kim, SY; Seo, D; Kim, J; White, TE; Brandariz-Nuñez, A; Diaz-Griffero, F; Yun, CH; Hollenbaugh, JA; Kim, B; Baek, D; Ahn, K (August 2014). "The ribonuclease activity of SAMHD1 is required for HIV-1 restriction.". Nature Medicine 20 (8): 936–41. doi:10.1038/nm.3626. PMID 25038827.
  9. Chahwan C, Chahwan R (May 2012). "Aicardi-Goutieres syndrome: from patients to genes and beyond". Clin. Genet. 81 (5): 413–20. doi:10.1111/j.1399-0004.2011.01825.x. PMID 22149989.
  10. 1 2 3 Li N, Zhang W, Cao X (November 2000). "Identification of human homologue of mouse IFN-gamma induced protein from human dendritic cells". Immunol. Lett. 74 (3): 221–4. doi:10.1016/S0165-2478(00)00276-5. PMID 11064105.
  11. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, Fuller JC, Jackson RM, Lamb T, Briggs TA, et al. (July 2009). "Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response". Nat. Genet. 41 (7): 829–32. doi:10.1038/ng.373. PMID 19525956.
  12. Welbourn S, Miyagi E, White TE, Diaz-Griffero F, Strebel K (2012). "Identification and characterization of naturally occurring splice variants of SAMHD1". Retrovirology 9: 86. doi:10.1186/1742-4690-9-86. PMC 3503569. PMID 23092512.
  13. 1 2 Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambiel I, Wabnitz G, Gramberg T, Panitz S, Flory E, Landau NR, Sertel S, Rutsch F, Lasitschka F, Kim B, König R, Fackler OT, Keppler OT (November 2012). "SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells". Nat. Med. 18 (11): 1682–7. doi:10.1038/nm.2964. PMID 22972397.
  14. 1 2 White TE, Brandariz-Nuñez A, Valle-Casuso JC, Amie S, Nguyen L, Kim B, Brojatsch J, Diaz-Griffero F (February 2013). "Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1". Virology 436 (1): 81–90. doi:10.1016/j.virol.2012.10.029. PMID 23158101.
  15. 1 2 3 4 Crow YJ, Rehwinkel J (October 2009). "Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity". Hum. Mol. Genet. 18 (R2): R130–6. doi:10.1093/hmg/ddp293. PMC 2758706. PMID 19808788.
  16. 1 2 3 Ayinde D, Casartelli N, Schwartz O (October 2012). "Restricting HIV the SAMHD1 way: through nucleotide starvation". Nat. Rev. Microbiol. 10 (10): 675–80. doi:10.1038/nrmicro2862. PMID 22926205.
  17. Kim CA, Bowie JU (December 2003). "SAM domains: uniform structure, diversity of function". Trends Biochem. Sci. 28 (12): 625–8. doi:10.1016/j.tibs.2003.11.001. PMID 14659692.
  18. Aravind L, Koonin EV (December 1998). "The HD domain defines a new superfamily of metal-dependent phosphohydrolases". Trends Biochem. Sci. 23 (12): 469–72. doi:10.1016/s0968-0004(98)01293-6. PMID 9868367.
  19. Yan J, Kaur S, Delucia M, Hao C, Mehrens J, Wang C, Golczak M, Palczewski K, Gronenborn AM, Ahn J, Skowronski J (April 2013). "Tetramerization of SAMHD1 Is Required for Biological Activity and Inhibition of HIV Infection". J. Biol. Chem. 288 (15): 10406–17. doi:10.1074/jbc.M112.443796. PMC 3624423. PMID 23426366.
  20. 1 2 White TE, Brandariz-Nuñez A, Valle-Casuso JC, Amie S, Nguyen LA, Kim B, Tuzova M, Diaz-Griffero F (April 2013). "The Retroviral Restriction Ability of SAMHD1, but Not Its Deoxynucleotide Triphosphohydrolase Activity, Is Regulated by Phosphorylation". Cell Host Microbe 13 (4): 441–51. doi:10.1016/j.chom.2013.03.005. PMID 23601106.
  21. 1 2 3 Mashiba M, Collins KL (January 2013). "Molecular mechanisms of HIV immune evasion of the innate immune response in myeloid cells". Viruses 5 (1): 1–14. doi:10.3390/v5010001. PMID 23420927.
  22. 1 2 Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, Yatim A, Schwartz O, Laguette N, Benkirane M (2012). "SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells". Retrovirology 9: 87. doi:10.1186/1742-4690-9-87. PMC 3494655. PMID 23092122.

Further reading

External links

This article is issued from Wikipedia - version of the Wednesday, January 06, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.